Aberrant expression of arrestin-1 and recoverin in kidney tumors


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Early diagnosis of renal cell carcinoma (RCC) is extremely difficult, due to the late development of clinical manifestations. The study of the aberrant expression of tumor-associated antigens and a production of autoantibodies to these proteins seems promising and novel method for RCC diagnosis. Aim: To evaluate the possibility of using arrestin-1 (Arr-1), recoverin (Rec) and autoantibodies against arrestin-1 (AAA1) and recoverin (AAR) as a kidney tumor biomarker. Materials and methods: Primary kidney tumors and metastases of 62 patients were investigated. For immunohistochemical studies, tissues were incubated with polyclonal antibodies against Rec and Arr1 as the main antibodies. Detection of AAR and AAA-1 in the serum of patients was performed using Western Blot analysis according to a standard protocol. Results: Among 62 tumors, renal cell carcinoma (RCC) constitutes 50 cases (86.4%), and oncocytoma was diagnosed in 12 patients (19.4%). In 11 (22%) cases of RCC, distant metastases were detected. Positive expression of Rec was observed in almost 71% of all types of kidney tumors. In 61.3% of patients with RCC, Arr-1 expression was seen. In the serum, AAR was found only in 1 patient (1.6%) with RCC. However, unlike AAR, AAA-1 in the serum of patients was observed much more often (75.8%). Conclusion: According to our data, the presence ofAAA1 in the serum, unlike AAR, can be considered as an early kidney tumor biomarker. The high expression of recoverin and arrestin-1 in kidney tumors suggests the use of these proteins in future as a marker for the diagnosis or even as a potential target for immunotherapy.

Full Text

Restricted Access

About the authors

L. V Tsoy

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: dr.lvtsoy@gmail.com
pathologist, assistant at the Department of Pathology of Medical Faculty named after A.I. Strukov Moscow, Russia

D. O Korolev

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: korolevdmitryo@gmail.com
Ph.D., senior ressearcher, urologist at the Institute for Urology and Human Reproductive Health Moscow, Russia

A. Z Vinarov

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: avinarov@mail.ru
MD, professor at the Institute for Urology and Human Reproductive Health Moscow, Russia

M. E Enikeev

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: enikmic@mail.ru
MD, professor at the Institute for Urology and Human Reproductive Health Moscow, Russia

Yu. V Lerner

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: julijalemer@inbox.ru
pathologist, assistant at the Department of Pathology of Medical Faculty named after A.I. Strukov Moscow, Russia

D. G Tsarichenko

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: tsarichenkodg@yandex.ru
MD, professor at the Institute for Urology and Human Reproductive Health Moscow, Russia

N. A Popov

GBUZ “City clinical oncological hospital No1 of the Moscow Health Department»

Email: dr.napopov@gmail.com
pathologist, laboratory of immunohistochemistry and molecular genetics Moscow, Russia

A. F Abdusalamov

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: boss4673@mail.ru
Ph.D., urologist at the Institute of Urology and Reproductive Health Moscow, Russia

Yu. P Gorobets

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: forexample009@gmail.com
6-year student of Medical Faculty Moscow, Russia

Yu. L Demidko

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: demidko1@mail.ru
MD, urologist at the Institute of Urology and Reproductive Health Moscow, Russia

V. A Varshavskiy

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: vavarsh@gmail.com
pathologist, MD, professor at the Department of Pathology of Medical Faculty named after A.I. Strukov Moscow, Russia

A. A Zamyatnin

FGAOU VO of I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University)

Email: zamyat@belozersky.msu.ru
Ph.D. in Biology, professor, director, Head of the Laboratory of Institute for Molecular Medicine of Science Moscow, Russia

L. M Rapoport

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: leonidrapoport@yandex.ru
MD, Professor, Deputy Director for Clinical Care of Institute for Urology and Human Reproductive Health Moscow, Russia

References

  1. Golovastova M.O. et al. Biomarkers of renal tumors: the current state and clinical perspectives. Current urology reports. 2017;18(1). Doi: 10.1007/ s11934-017-0655-1
  2. Are C. et al. A review of global cancer burden: Trends, challenges, strategies, and a role for surgeons. J Surg Oncol. 2013;107(2):221-226. doi: 10.1002/jso.23248.
  3. Dizhoor A.M. et al. Role of the acylated amino terminus of recoverin in Ca2+-dependent membrane interaction. Science. 1993;259(5096):829-832.
  4. Polans A.S. et al. A photoreceptor calcium binding protein is recognized by autoantibodies obtained from pa9tients with cancer-associated retinopathy. Journal of Cell Biology. 1991;112(5):981-989.
  5. Bazhin A. V. et al. Recoverin as a paraneoplastic antigen in lung cancer: The occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors. Lung Cancer. 2004;44(2):193-198.
  6. Moch H. et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70( 1):93-105. Doi: 10.1016/j. eururo.2016.02.029.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies